16,845 Shares in SPDR S&P Biotech ETF (XBI) Acquired by Marshall Wace LLP

Share on StockTwits

Marshall Wace LLP acquired a new position in SPDR S&P Biotech ETF (NYSEARCA:XBI) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 16,845 shares of the exchange traded fund’s stock, valued at approximately $1,615,000.

Other institutional investors also recently made changes to their positions in the company. Howard Capital Management grew its stake in shares of SPDR S&P Biotech ETF by 2.5% in the third quarter. Howard Capital Management now owns 154,827 shares of the exchange traded fund’s stock worth $14,843,000 after acquiring an additional 3,780 shares during the last quarter. Rafferty Asset Management LLC grew its stake in shares of SPDR S&P Biotech ETF by 114.1% in the third quarter. Rafferty Asset Management LLC now owns 941,464 shares of the exchange traded fund’s stock worth $90,258,000 after acquiring an additional 501,695 shares during the last quarter. Natixis boosted its stake in SPDR S&P Biotech ETF by 5.5% during the second quarter. Natixis now owns 49,498 shares of the exchange traded fund’s stock worth $4,712,000 after buying an additional 2,594 shares in the last quarter. Adirondack Trust Co. boosted its stake in SPDR S&P Biotech ETF by 73.6% during the third quarter. Adirondack Trust Co. now owns 5,895 shares of the exchange traded fund’s stock worth $565,000 after buying an additional 2,500 shares in the last quarter. Finally, Winfield Associates Inc. boosted its stake in SPDR S&P Biotech ETF by 18.3% during the third quarter. Winfield Associates Inc. now owns 34,793 shares of the exchange traded fund’s stock worth $3,336,000 after buying an additional 5,393 shares in the last quarter.

XBI opened at $73.65 on Wednesday. SPDR S&P Biotech ETF has a fifty-two week low of $72.42 and a fifty-two week high of $101.55.

WARNING: “16,845 Shares in SPDR S&P Biotech ETF (XBI) Acquired by Marshall Wace LLP” was reported by Week Herald and is the property of of Week Herald. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://weekherald.com/2018/12/19/16845-shares-in-spdr-sp-biotech-etf-xbi-acquired-by-marshall-wace-llp.html.

SPDR S&P Biotech ETF Company Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Recommended Story: Leveraged Buyout (LBO)

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply